» Articles » PMID: 11150414

Which Hepatocyte Will It Be? Hepatocyte Choice for Bioartificial Liver Support Systems

Overview
Journal Liver Transpl
Date 2001 Jan 11
PMID 11150414
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Liver failure, notwithstanding advances in medical management, remains a cause of considerable morbidity and mortality in the developed world. Although bioartificial liver (BAL) support systems offer the potential of significant therapeutic benefit for such patients, many issues relating to their use are still to be resolved. In this review, these issues are examined in terms of the functions required, the cells of choice in such a system, and the most appropriate environment to optimize the function of such cells. The major functions identified to date for a BAL are ammonia detoxification and biotransformation of toxic compounds, although this somewhat belies the complexity of the functions required. Two practical choices for cell type within such a system are xenogenic hepatocytes and immortalized human hepatocyte lines. Both these choices have drawbacks, such as the transmission of zoonoses and malignant infiltration, respectively. Finally, improvements in culture conditions, such as supplemented media, biodegradable scaffolds, and coculture, offer the possibility of prolonging the differentiated function of hepatocytes in a BAL.

Citing Articles

The Story of Ammonia in Liver Disease: An Unraveling Continuum.

Anand A, Acharya S J Clin Exp Hepatol. 2024; 14(4):101361.

PMID: 38444405 PMC: 10910335. DOI: 10.1016/j.jceh.2024.101361.


Genome-wide expression profiling reveals increased stability and mitochondrial energy metabolism of the human liver cell line HepaRG-CAR.

Adam A, Jongejan A, Moerland P, van der Mark V, Elferink R, Chamuleau R Cytotechnology. 2020; 72(3):377-395.

PMID: 32130581 PMC: 7225227. DOI: 10.1007/s10616-020-00384-w.


Challenges and Opportunities in the Design of Liver-on-Chip Microdevices.

Ehrlich A, Duche D, Ouedraogo G, Nahmias Y Annu Rev Biomed Eng. 2019; 21:219-239.

PMID: 31167098 PMC: 7004816. DOI: 10.1146/annurev-bioeng-060418-052305.


Novel sericin-based hepatocyte serum-free medium and sericin's effect on hepatocyte transcriptome.

Huang Y, Peng Q, Li H, Jia Z, Li Y, Gao Y World J Gastroenterol. 2018; 24(30):3398-3413.

PMID: 30122879 PMC: 6092578. DOI: 10.3748/wjg.v24.i30.3398.


Clinical Hepatocyte Transplantation: What Is Next?.

Squires J, Soltys K, McKiernan P, Squires R, Strom S, Fox I Curr Transplant Rep. 2018; 4(4):280-289.

PMID: 29732274 PMC: 5932623. DOI: 10.1007/s40472-017-0165-6.